 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...345678910111213...1920» |
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Journal: Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. (Pubmed Central) - Mar 4, 2022
Authors noted that use of treatment regimens including a protease inhibitor did not increase the risk of hepatic decompensation. We would like to present additional data, particularly regarding the use of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy in this difficult-to-cure patient population.
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% (clinicaltrials.gov) - Mar 2, 2022
P4, N=350, Not yet recruiting, Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- || ribavirin / Generic mfg.
Clinical, Journal: Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. (Pubmed Central) - Feb 24, 2022
A PWUD-tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro-elimination programs providing dedicated care are key drivers of success.
- sofosbuvir/velpatasvir / Generic mfg.
Industry Symposium 3 - Gilead Sciences (Combating Hepatitis C Virus by Epclusa to Reach Elimination) (R2, 3F) - Feb 24, 2022 - Abstract #APASL2022APASL_485;
Despite history of drug addiction, social instability and logistic barriers, micro-elimination programs providing dedicated care are key drivers of success. Sponsored by Gilead
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. (Pubmed Central) - Feb 10, 2022
Sponsored by Gilead Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen, sofosbuvir/velpatasvir, provides successful strategies toward HCV micro-elimination among prisoners.
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - Feb 10, 2022
P2, N=20, Recruiting, Sponsor: Baylor Research Institute
Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen, sofosbuvir/velpatasvir, provides successful strategies toward HCV micro-elimination among prisoners. Trial completion date: Feb 2021 --> Dec 2022 | Trial primary completion date: Jan 2021 --> Dec 2022
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. (Pubmed Central) - Feb 9, 2022
Trial completion date: Feb 2021 --> Dec 2022 | Trial primary completion date: Jan 2021 --> Dec 2022 While risk of incident ALT elevations was increased among PI-based DAA initiators in both FIB-4 groups, risk of severe hepatic dysfunction and hepatic decompensation did not differ between PI and non-PI-based DAA initiators in either FIB-4 group.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. (Pubmed Central) - Feb 8, 2022
P3
While risk of incident ALT elevations was increased among PI-based DAA initiators in both FIB-4 groups, risk of severe hepatic dysfunction and hepatic decompensation did not differ between PI and non-PI-based DAA initiators in either FIB-4 group. In this randomised study in recent HCV infection, 6 weeks sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12 weeks duration.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Clinical data, Journal, Real-world evidence: Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. (Pubmed Central) - Feb 8, 2022
In this randomised study in recent HCV infection, 6 weeks sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12 weeks duration. The SOF/VEL regimen showed good virological efficacy and acceptable safety even in patients with HCV-related decompensated cirrhosis.
- sofosbuvir/velpatasvir / Generic mfg.
A MODEL TO ERADICATE HCV IN UNDOCUMENTED MIGRANTS AND LOW-INCOME REFUGEES IN ITALY ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_1137;
The HCV RNA-positive subjects have been treated with sofosbuvir-velpatasvir for 12 weeks and followed for 12 months from the end of therapy...No subject had adverse event. This model seems to be effective to eradicate HCV infection among a difficult-to-manage population, such as undocumented migrants and low-income refugees
- sofosbuvir/velpatasvir / Generic mfg.
ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_1127;
ACTG A5360 (MINMON) was a single-arm, open-label, multinational trial to evaluate the safety and efficacy of 12 weeks of Sofosbuvir/Velpatasvir (SOF/VEL) with reduced in-person visits and laboratory monitoring...Programs seeking to scale up the minimal monitoring strategy may consider additional support for younger individuals or those reporting current or past substance use. Week 4 self-reported adherence may also help identifying those who may need additional support.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_1126;
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is a pan-genotypic direct active antiviral (DAA) regimen approved for patients who have previously failed anti-HCV treatment with other DAAs...The type of previous regimens included sofosbuvir/ledipasvir in 50% patients, ombitasvir/paritaprevir/ritonavir plus dasabuvir in 9.4%, sofosbuvir plus daclatasvir in 9.4%, elbasvir/grazoprevir in 9.4%, glecaprevir/pibrentasvir in 9.4% and 13.4% other regimens...Liver cirrhosis and genotype did not influence treatment response (SVR by ITT 90% for cirrhosis and 85.8% for G3). Our findings suggest that SOF/VEL/VOX is a highly effective regimen for treatment of coinfected patients previously failing to DAA regimens, across all genotypes and in the presence of cirrhosis.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination. (Pubmed Central) - Feb 4, 2022
The patient was prescribed Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) 1 tablet by mouth daily for 24 weeks, but finished his course 18 days late due to poor compliance and treatment interruptions. The active role of the clinical pharmacist in the hepatology clinic facilitated the patient's ongoing engagement in care, leading to treatment success.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Retrospective data, Review, Journal: Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review. (Pubmed Central) - Feb 2, 2022
The active role of the clinical pharmacist in the hepatology clinic facilitated the patient's ongoing engagement in care, leading to treatment success. Treatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir/velpatasvir for the treatment of Hepatitis C in pediatric patients. (Pubmed Central) - Jan 27, 2022
No major differences in efficacy and safety profile have been described. Limited access to treatment still is a major issue, especially in low and middle-income countries.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand. (Pubmed Central) - Jan 27, 2022
Limited access to treatment still is a major issue, especially in low and middle-income countries. HCV treatment using DAA among prisoners through universal test-and-treat approach led by prison health care workers is highly effective and safe, and such model can potentially help to facilitate the goals of HCV microelimination among prisoners in Thailand.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
ABO INCOMPATIBLE KIDNEY TRANSPLANT IN HIV POSITIVE RECIPIENT COINFECTED WITH BOTH HEPATITIS B AND HEPATITIS C VIRUS - A LEARNING EXPERIENCE (Poster Area (Virtual)) - Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1392;
with the advancement in drugs, interactions are minimal and kidney transplantation have shown acceptable results. Coinfections pose a challenge, yet the growing literature indicates that HIV-infected patients can be transplanted safely and enjoy posttransplant outcomes comparable to their uninfected counterparts.
- || Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Reimbursement, Journal, Medicare: Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. (Pubmed Central) - Jan 20, 2022
The results of this cross-sectional study suggest that authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare. Instead, these drugs allow manufacturers to offer products at a lower list price without materially lowering net prices or profits.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: RCT: HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial (clinicaltrials.gov) - Jan 18, 2022
P4, N=100, Active, not recruiting, Sponsor: Alexandria University
Instead, these drugs allow manufacturers to offer products at a lower list price without materially lowering net prices or profits. Recruiting --> Active, not recruiting
- | ribavirin / Generic mfg.
Journal: The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. (Pubmed Central) - Jan 15, 2022
In the real-world setting, sofosbuvir-based treatment is safe, effective, and well tolerated in AN/AI patients. Sustained virologic response was high regardless of HCV genotype or cirrhosis status.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). (Pubmed Central) - Jan 13, 2022
P, P3
Sustained virologic response was high regardless of HCV genotype or cirrhosis status. Outreach strategies with mass screenings and on-site group treatment greatly facilitated HCV microelimination in the haemodialysis population.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment closed: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Jan 11, 2022
P=N/A, N=461, Active, not recruiting, Sponsor: Gilead Sciences
Outreach strategies with mass screenings and on-site group treatment greatly facilitated HCV microelimination in the haemodialysis population. Enrolling by invitation --> Active, not recruiting
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. (Pubmed Central) - Jan 11, 2022
Enrolling by invitation --> Active, not recruiting SOF/VEL with or without low-dose RBV is effective and well-tolerated in HCV-infected patients with severe RI.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. (Pubmed Central) - Jan 11, 2022
Moreover, all eight individuals received follow-up assessments at 44 weeks from the beginning of their 12-week treatments of sofosbuvir/velpatasvir (after-treatment week 32)...The newly identified resistance-associated amino acid substitutions may help inform future clinical treatments. We believe that our study makes a significant contribution to the literature based on the results described above.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, HEOR, Real-world evidence: Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C. (Pubmed Central) - Jan 11, 2022
Bunner owns stock in UnitedHealth group, parent company of Optum. A poster based on selected data from this study was presented at the AMCP 2021 Virtual Meeting, April 12-16, 2021.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial completion date, Trial primary completion date: TEMPO: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (clinicaltrials.gov) - Jan 11, 2022
P=N/A, N=300, Recruiting, Sponsor: Kirby Institute
A poster based on selected data from this study was presented at the AMCP 2021 Virtual Meeting, April 12-16, 2021. Trial completion date: Dec 2022 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, Real-world evidence: Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis. (Pubmed Central) - Jan 6, 2022
Trial completion date: Dec 2022 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Pangenotypic DAAs are well tolerated by and yield high SVR rates in patients with mixed genotype HCV infection.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. (Pubmed Central) - Jan 1, 2022
Pangenotypic DAAs are well tolerated by and yield high SVR rates in patients with mixed genotype HCV infection. SOF/VEL was highly effective and well tolerated in Taiwanese patients, irrespective of viral genotype, liver disease severity, and comorbidities.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Hepatitis C: Diagnosis and Management. (Pubmed Central) - Dec 29, 2021
In patients with compensated cirrhosis, posttreatment surveillance for hepatocellular carcinoma and esophageal varices should include abdominal ultrasonography (with or without alpha fetoprotein) every six months and upper endoscopy every two to three years. In the absence of cirrhosis, no liver-related follow-up is recommended.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study (Pubmed Central) - Dec 29, 2021
Severe side effects (edema and fatigue) occurred in 2 patients, one of whom needed a short-term interruption of treatment due to fatigue. In this real-world cohort study, 12-week SOF/VEL regimen with or without ribavirin achieved high SVR12 rates (96.5%-100% overall) with excellent safety profile among patients with HCV GT1/2/3 infection including patients with GT3 and cirrhosis, and led to improvement of liver function.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis. (Pubmed Central) - Dec 27, 2021
Conclusion The combination of sofosbuvir and velpatasvir is highly effective and safe in patients with HCV with or without cirrhosis. However, this combination's efficacy was slightly higher in non-cirrhotic patients (98.3%) than in cirrhotic patients (89.7%).
- | sofosbuvir/velpatasvir / Generic mfg.
Preclinical, Journal: Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. (Pubmed Central) - Dec 16, 2021
Both viruses responded to sofosbuvir and velpatasvir in a dose-dependent manner...In conclusion, we have developed infectious clones for genotype 1b and shown a novel strategy for culture adaptation of HCV isolates by using a genetically close backbone sequence. Furthermore, this study provides transcriptional landscape of HCV 1b-infected hepatoma cells facilitating the study of genotype 1b infection.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Comparative evaluation of different mathematical models for simultaneous UV spectrophotometric quantitative analysis of velpatasvir and sofosbuvir. (Pubmed Central) - Dec 16, 2021
Pre-processing of the spectral data was applied and resulted in the exclusion of the spectral region from 200 to 230 nm due to noise. The described methods were successfully applied to the spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in Epclusa® tablets.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Liver Disease: Hepatitis C. (Pubmed Central) - Dec 16, 2021
Management results in rates of virologic cure of greater than 95% across genotypes. Patients who do not achieve SVR at 12 weeks should be referred to a subspecialist experienced in management of treatment failure.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. (Pubmed Central) - Dec 5, 2021
Achievement of SVR with sofosbuvir/velpatasvir improved the liver functional reserve at 12 weeks post-treatment and maintained the stable effects until 48 weeks post-treatment in patients with decompensated cirrhosis. Specifically, the patients with less advanced conditions had the likelihood of improving to Child-Pugh class A at 48 weeks post-treatment.
- |||| sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) - Dec 2, 2021
P4, N=100, Not yet recruiting, Sponsor: Catherine Chappell
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. (Pubmed Central) - Dec 1, 2021
Real-world efficacy of SOF/VEL treatment for patients with decompensated cirrhosis was similar to Japanese phase 3 study, although treatment discontinuation and death related to liver disease occurred. In patients with poor hepatic reserve, whether it improves continuously after viral clearance requires further evaluation.
- || ribavirin / Generic mfg.
Clinical, Journal, Real-world evidence: Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C. (Pubmed Central) - Dec 1, 2021
RAS analysis in 17 randomly selected patients did not reveal any dominant substitutions in NS5A or NS5B region affecting SVR12, though several novel mutations were observed. In conclusion, re-treatment of CHC patients with prior DAA failure using pangenotypic DAA is associated with high SVR12 rates irrespective of genotype or presence of RAS.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy. (Pubmed Central) - Nov 29, 2021
In conclusion, re-treatment of CHC patients with prior DAA failure using pangenotypic DAA is associated with high SVR12 rates irrespective of genotype or presence of RAS. No abstract available
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Reply to Huang et. al. [JHEPAT-D-19-00400R1]. (Pubmed Central) - Nov 29, 2021
No abstract available No abstract available
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. (Pubmed Central) - Nov 24, 2021
No abstract available Overall, SOF/VEL and LDV/SOF regimens are more likely to be cost-effective among various subgroups of Chinese patients with CHC.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Observational data, Retrospective data, Journal, Real-world evidence: Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. (Pubmed Central) - Nov 24, 2021
Afdhal is a paid consultant/advisory board member for Gilead, Echosens, Ligand, Shionogi, and Trio Health; owns stock in Spring-Bank and Allurion and has stock options in SpringBank; receives royalty income from UpToDate; and is on the board of directors for the nonprofit Liver Institute for Education and Research. Data from this study were presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2019; November 8-12, 2019; Boston, MA, and the European Association for Study of the Liver (EASL) International Liver Congress 2020; August 27-29, 2020; virtual.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) - Nov 22, 2021
P2, N=20, Active, not recruiting, Sponsor: Mary E. Keebler, MD
Data from this study were presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2019; November 8-12, 2019; Boston, MA, and the European Association for Study of the Liver (EASL) International Liver Congress 2020; August 27-29, 2020; virtual. Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants. (Pubmed Central) - Nov 16, 2021
We previously reported HCV transmission of 13% among D+/R- transplants with 2- to 4-day pangenotypic sofosbuvir/velpatasvir (SOF/VEL) perioperative prophylaxis, where one patient with HCV transmission was a nonresponder to first-line full-course DAA...All patients with HCV transmission achieved sustained virologic response post-full course therapy (including one non-responder from initial trial). A 1:1 matched analysis (N=102) with contemporary HCV D-/R- transplants (controls) showed that although the pre-transplant wait time was significantly shorter for D+/R- compared with D-/R- (mean: 1.8 vs 4.4 years; p<0.001), there were no differences in infections, rejection, development of de-novo donor-specific antibody, or transplant outcomes up to 6 months of transplant.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Clinical, Journal: Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. (Pubmed Central) - Nov 12, 2021
This real-world study confirms high efficacy of SOF/VEL/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including those with GT3 and cirrhosis. Treatment was well tolerated in most however serious AEs can occur in those with advanced liver disease.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, Real-world evidence: Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. (Pubmed Central) - Nov 5, 2021
Five drug discontinuations occurred due to AEs (bilirubin elevation: 3; dermatological issues: 2). Pangenotypic DAAs GLE/PIB and SOF/VEL are effective and well tolerated, achieving high SVR12 rates for patients with all HCV genotypes.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. (Pubmed Central) - Nov 5, 2021
Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate (eGFR) declines than patients with CKD stage 2 (-0.42 mL/min/1.73m2/month; p = 0.01) or stage 3 (-0.56 mL/min/1.73m2/month; p < 0.001). SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, Combination therapy: Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. (Pubmed Central) - Nov 4, 2021
With combination therapy of sofosbuvir/velpatasvir plus ribavirin (SOF/VEL+RBV) for 24 weeks, all 3 patients had achieved a sustained viral response (SVR) at 24 weeks after completing treatment. SOF/VEL+RBV therapy was effective for retreatment of HCV after failure of GLE/PIB therapy.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India. (Pubmed Central) - Nov 4, 2021
Expected net benefits of treatment are substantial for non-cirrhotic (NC) and compensated cirrhotic (CC) patients (ranging from 5,98,003 INR for NC women to 1,05,25,504 INR for CC men). Increased earnings are not sufficient to fully offset cost of treatment for decompensated cirrhotic individuals but treatment may still be justified on the basis of the intrinsic value of health improvements and other treatment benefits.
- | sofosbuvir/velpatasvir / Generic mfg.
Retrospective data, Journal: Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors. (Pubmed Central) - Oct 30, 2021
Renal function was stable in all patients. CONCLUSIONS Sofosbuvir/Velpatasvir pre- and post-transplantation treatment was effective and safe in HCV-uninfected recipients who received a transplant kidney from HCV-infected donors.